Pixalate’s April 2025 Top Grossing Mobile & CTV Apps in EMEA: ‘Block Blast!’ Tops Apple App Store in UK, Germany; ‘SimCity’ Led on Google Play Store in UK, Spain, Germany

1 day ago

According to Pixalate's research, ‘Pro Des Mots’ led on Apple App Store in France, ‘Sudoku’ was No. 1 in Israel…

GEN Restaurant Group Announces First Quarter 2025 Financial Results

1 day ago

CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), owner of…

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

1 day ago

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma…

Waldencast Reports Q1 2025 Financial Results

1 day ago

Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4…

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

1 day ago

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of…

Hyperfine, Inc. Reports First Quarter 2025 Financial Results

1 day ago

GUILFORD, Conn., May 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined…

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

1 day ago

REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita’s potential to maintain weight loss…

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

1 day ago

– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units…

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

1 day ago

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly…

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

1 day ago

Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for…

This website uses cookies.